Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026

Summary

In a post hoc analysis of the phase 3 REDEFINE 1 trial, 67.8% of adults treated with investigational CagriSema 2.4 mg / 2.4 mg were early responders, achieving at least 5% weight loss by week 81 Women were more likely to be early responders than delayed responders (71.8% vs 59.5%)1 In a...